NCT02990338: Phase 3 - Isatuximab, Pomalidomide & Dex VS Pom & Dex in relapsed Myeloma (ICARIA-MM)
ICARIA Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory...
Dec 13, 2016
305
NCT02541383: Phase 3 - Bortezomib, thalidomide, dex +/-Daratumumab before & after ASCT (CASSIOPEIA)
The CASSIOPEIA trial IFM / HOVON IFM 2015-01 HOVON HO131 MM Newly Diagnosed Multiple Myeloma A Study to Evaluate Daratumumab in...
Dec 31, 2015
724
NCT02336815 : Phase 2 - Selinexor Treatment of Refractory Myeloma (STORM)
STORM Selinexor Treatment of Refractory Myeloma (STORM) This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg...
Dec 30, 2015
230
NCT02412878: Phase 3 - Once-weekly vs Twice-weekly Carfilzomib With Dexa in Relapsed MM (ARROW)
Phase 3 A.R.R.O.W. trial - ARROW Kd The purpose of the study is to compare the progression-free survival (PFS) of once-weekly carfilzomib...
Dec 4, 2015
275
NCT02514239: Phase 1 - Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Myeloma Patients
An Open Label, Phase I, Dose Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of...
Dec 1, 2015
194
NCT02076009: Phase 3 - Daratumumab, Lenalidomide & Dex (DRd) VS Len & Dexa (Rd) - MMY3003 (POLLUX)
MMY3003 (POLLUX) Study NCT02076009: Phase 3: A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and...
Dec 19, 2014
398
NCT02197221: Phase 3: Bortezomib-Melphalan Conditioning Regimen vs Melphalan - Frontline Transplant
IFM2014-02 NCT02197221: Phase 3: Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With...
Dec 17, 2014
79
NCT02181413: Phase 3 - TOURMALINE-MM3 -Oral Ixazomib Citrate (MLN9708) Maintenance in NDMM Post ASCT
TOURMALINE-MM3 A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous...
Dec 13, 2014
373
NCT02252172 : Phase 3 - Dara, Lena & Dex VS Len & Dex in previously untreated Myeloma - MAIA STUDY
The MAIA Study NCT02252172: Phase 3: Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in...
Dec 12, 2014
499
NCT02316106: Phase 2 - A Study to Evaluate 3 Dose Schedules of Daratumumab in SMM - CENTAURUS
CENTAURUS A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma The purpose of this study...
Dec 12, 2014
171
NCT02312258: Phase 3: TOURMALINE-MM4 - Oral Ixazomib Maintenance Therapy in NDMM-TIE
TOURMALINE-MM4 Trial NCT02312258: Phase 3: A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple...
Dec 9, 2014
66
NCT01794520: Phase 1/2: Study Evaluating ABT-199 in Participants With Relapsed or Refractory MM
NCT01794520: Phase 1/2: Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma The phase 1 primary...
Dec 20, 2013
123
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE) The purpose of this study is to assess the...
Dec 12, 2013
90
NCT01971658: Phase 3: Efficacy Study Comparing VTD Versus VCD as Induction NDMM - IFM2013-04
IFM2013-04 NCT01971658: Phase 3: Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone...
Dec 5, 2013
237
NCT01568866: Phase 3 - Carfilzomib and Dex Vs Bortezomib & Dex for Relapsed Myeloma (ENDEAVOR)
The ENDEAVOR Trial KD Vs Vd The primary objective of this study was to compare progression-free survival in patients with multiple...
Dec 12, 2012
476
NCT01592370: Phase 1/2: Safety and Effectiveness of Nivolumab and Daratumumab in Multiple Myeloma
NCT01592370: Phase 1/2: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in...
Dec 8, 2012
97
NCT01080391: Comparing Carfilzomib, Lenalidomide & Dex (CRd) vs Lenalidomide and Dex (Rd) - ASPIRE
THE ASPIRE TRIAL Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in...
Dec 10, 2010
547
NCT01191060: Phase 3 - IFM 2009 - (IFM/DFCI2009) Conventional dose RVD to High-Dose + ASCT -NDMM
IFM 2009 IFM/DFCI2009 The Intergroupe Francophone du Myelome 2009 trial Study Comparing Conventional Dose Combination RVD to High-Dose...
Dec 3, 2010
464
NCT00689936: Phase 3 - Lenalidomide+low dose dex vs Melphalan, Prednisone, Thalidomide in NDMM FIRST
FIRST study IFM 07-01 CC-5013-MM020 Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan,...
Dec 14, 2008
442